CN104758295A - Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug - Google Patents
Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug Download PDFInfo
- Publication number
- CN104758295A CN104758295A CN201510103957.3A CN201510103957A CN104758295A CN 104758295 A CN104758295 A CN 104758295A CN 201510103957 A CN201510103957 A CN 201510103957A CN 104758295 A CN104758295 A CN 104758295A
- Authority
- CN
- China
- Prior art keywords
- anemia
- muell
- miq
- arg
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007502 anemia Diseases 0.000 title claims abstract description 46
- XURLTFUKDPZAPN-QFIPXVFZSA-N Cleistanone Natural products O(C)[C@H]1OC(=O)c2c(-c3cc4OCOc4cc3)c3c(c(O)c12)cc(OC)c(OC)c3 XURLTFUKDPZAPN-QFIPXVFZSA-N 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 4
- GEIFQLXIDUDMNZ-PCJVTFPHSA-N (4aR,4bR,6aR,8S,10aR,10bR,12R,12aR)-12-hydroxy-1,1,1',1',4a,10a,10b-heptamethyl-3'-methylidenespiro[3,4,4b,5,6,6a,7,9,10,11,12,12a-dodecahydrochrysene-8,2'-cyclopentane]-2-one Chemical compound CC1(C)CCC(=C)[C@@]11C[C@@H](CC[C@H]2[C@]3(C[C@@H](O)[C@H]4C(C)(C)C(=O)CC[C@@]42C)C)[C@@]3(C)CC1 GEIFQLXIDUDMNZ-PCJVTFPHSA-N 0.000 claims abstract description 28
- 241000785597 Cleistanthus Species 0.000 claims description 27
- 150000002576 ketones Chemical class 0.000 claims description 26
- 239000002023 wood Substances 0.000 claims description 26
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 241001597008 Nomeidae Species 0.000 claims description 19
- 210000003743 erythrocyte Anatomy 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- -1 phosphate amine Chemical class 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002607 hemopoietic effect Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000010437 erythropoiesis Effects 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000035220 Dyserythropoietic Congenital Anemia Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000004440 congenital dyserythropoietic anemia Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the fields of organic synthesis and medicinal chemistry and particularly relates to an O-(triazolyl)ethyl derivative of cleistanone, a preparation method of the same, and an application of the same in preparation of an anti-low-erythrocyte anemia drug. In the invention, a new derivative of the cleistanone is synthesized with the preparation method thereof disclosed. A pharmacologic experiment proves that the O-(triazolyl)ethyl derivative of the cleistanone has an anti-low-erythrocyte anemia function, thereby achieving value of developing the anti-low-erythrocyte anemia drugs.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant, preparation method and its usage.
Background technology
Based on different clinical characters, anemia has different classification.As: divide acute and chronic anemia by anemia tempo; Hyperplastic anemia (as hemolytic anemia, iron deficiency anemia, megaloblastic anemia etc.) and Hypolasia anemia (as aplastic anemia) is divided by bone marrow red system proliferative conditions.
The normal classification from anemia pathogenesis and the cause of disease clinically:
1. erythropoiesis minimizing property anemia
The anomalous effects erythropoiesis of hematopoietic cell, marrow stromal cell and hemopoietic raw material, can form erythropoiesis minimizing property anemia.
(1) hematopoietic stem/progenitor cells caused by abnormal anemia
1) aplastic anemia (AA) AA is a kind of marrow hematopoiesis function failure disease, damages relevant with the hematopoietic stem/progenitor cells of former and secondary.The pathogenesis of parts whole blood cytopenia and B cell produce anti-medullary cell autoantibody, and then destroy or suppress myeloid element relevant.
2) pure red cell aplasia anemia (PRCA) PRCA refers to that bone marrow erythroid hematopoiesis stem/progenitor cells suffers damage, and then causes anemia.According to the cause of disease, this disease can be divided into congenital and posteriority two class.Congenital PRCA and Diamond-Blackfan syndrome is caused by heredity; Posteriority PRCA comprises former, secondary two class.Scholar is had to find have self EPO or normoblast antibody in part constitutional PRCA patients serum.Secondary cases PRCA mainly contains medicine relationship type, (antibacterial and virus, as piconavirus B to infect relationship type
19, hepatitis virus etc.), autoimmune disease relationship type, lymphoproliferative disease relationship type (as thymoma, lymphoma, plasma cell dyscrasia and Lymphocytic leukemia etc.) and acute aplastic crisis etc.
3) congenital dyserythropoietic anemia (CDA) CDA be a class heritability red system stem/progenitor cells optimum clone caused by abnormal, the refractory anemia that is feature with red system ineffective hematopoiesis and paramophia.According to mode of inheritance, this disease can be divided into the hidden flight of steps leading to a palace hall genotype of autosome and dominant inheritance's type.
4) these disease hematopoietic stem/progenitor cells of hemopoietic system malignant clone disease there occurs the exception of matter, comprise myelodysplastic syndrome and all kinds of hematopoietic system cancer disease as leukemia etc.The former is because DH, high hypertrophy, and hemolysis in situ, appears in high apoptosis; The latter's neoplastic hyperplasia, low apoptosis and low differentiation, hemopoietic regulates and is also affected, thus makes normal mature erythrocytopenia and anemia occurs.
(2) hematopoieticmicroenviron-ment caused by abnormal anemia
Hematopoieticmicroenviron-ment comprises bone marrow matrix, stromal cell and cytokine.
1) bone marrow neoplasms of sick, the various extramedullary tumor disease of bone marrow matrix and stromal cell impaired Anemia BMN, myelofibrosis, myelosclerosis, marble and various infection or non-infectious osteomyelitis, all can because of damage bone marrow matrix and stromal cell, hematopoieticmicroenviron-ment occurs abnormal and affects hemopoietic.
2) hematopoietic regulators horizontal abnormality Anemia stem cell factor (SCF), interleukin (IL), grain-monosystem colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), erythropoietin (EPO), thrombopoietin (TPO), PDGF (TGF), tumor necrosis factor (TNF) and interferon (IFN) etc. all have positive negative regulation hemoposieis.Renal insufficiency, hepatopathy and hypophysis or hypothyroidism etc. time to produce EPO not enough; Neoplastic disease or some viral infection can induce body to produce more hemopoietic negative regulatory factor as TNF, IFN, inflammatory factor etc., all can cause ACD (ACD).
(3) hemopoietic insufficient raw material or Use barriers Anemia
Hemopoietic raw material refers to hematopoietic cell proliferation, differentiation, the necessary material of metabolism, as protein, lipid, vitamin (folic acid, vitamin B12 etc.), trace element (ferrum, copper, zinc etc.) etc.Any one hemopoietic insufficient raw material or Use barriers all may cause erythropoiesis to reduce.
1) folic acid or vitamin B
12to lack or Use barriers Anemia causes the megaloblastic anemia that body folic acid or vitamin B12 definitely or relatively lack or Use barriers can cause due to various physiology or pathological factor.
2) iron deficiency and ferrum Use barriers anemia this be modal anemia clinically.Iron deficiency and ferrum Use barriers affect haemachrome synthesis, have and claim such anemia to be haemachrome resulting anomaly anemia.The red cell morphology of such anemia diminishes, and central olistherozone expands, and belongs to microcytic hypochromic anemia.
2. hemolytic anemia (HA)
I.e. hematoclasis too much property anemia.
3. hemorrhagic anemia
Divide acute and chronic according to the speed of losing blood, chronic blood loss anemia often merges iron deficiency anemia.Can be divided into disorders of blood coagulation (as idiopathic thrombocytopenic purpura, hemophilia and severe liver disease etc.) make peace non-go out caused two classes of disorders of blood coagulation (as wound, tumor, tuberculosis, bronchiectasis, peptic ulcer, hemorrhoid and gynaecopathia etc.).
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The compound Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone that the present invention relates to is one and within 2011, delivers (Van Trinh ThiThanh et al., 2011.Cleistanone:A Triterpenoid from Cleistanthus indochinensis with aNew Carbon Skeleton.
volume 2011, Issue 22,pages 4108 – 4111, August 2011) compound, we have carried out structural modification to compound Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone, obtain a new Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant, and its anti-erythrocyte low property anemia activity is evaluated, it is active that it has anti-erythrocyte low property anemia.
Summary of the invention
The invention discloses a Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant, its structure is:
Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) of the present invention is by method preparation below:
(1) Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone (I) and glycol dibromide are obtained by reacting the O-bromoethyl derivant (II) of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone;
(2) the O-bromoethyl derivant (II) of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone obtains Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) with 1,2,3-triazole generation substitution reaction.
The preparation method of further Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) is:
(1) 440mg compound Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone (I) is dissolved in 10mL benzene, in solution, adds the tetrabutyl ammonium bromide of 0.04g, the glycol dibromide of 3.760g and 50% sodium hydroxide solution of 6mL; Mixture stirs 24h at 25 degrees Celsius; After 24h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution; Then use water and saturated common salt water washing 3 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product; Product crude product purification by silica gel column chromatography, mobile phase is: petroleum ether/acetone=100:1, v/v, collects the yellow yellow solid concentrating elution band namely to obtain the O-bromoethyl derivant (II) of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone.
(2) the O-bromoethyl derivant of the Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr of 273mg wood ketone Cleistanone is dissolved in the middle of 20mL acetonitrile, adds the Anhydrous potassium carbonate of 345mg wherein, the potassium iodide of 84mg and 1,2, the 3-triazole of 2760mg, mixture reflux 4h; After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction three times, merge organic facies; Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product; Product crude product purification by silica gel column chromatography, mobile phase is: petroleum ether/acetone=100:0.5, v/v, collects the faint yellow colloidal solid that namely faint yellow concentrated elution band obtains Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III).
Compound disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
The object of the present invention is to provide the new application of the compounds of this invention in pharmaceutical field.
The present invention relates to the compounds of this invention as the application in preparation treatment erythrocyte low property anemia medicine.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 compound Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone
Document (the Van Trinh Thi Thanh et al. that the people such as the preparation method reference Van Trinh Thi Thanh of compound Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone (I) deliver, 2011.Cleistanone:A Triterpenoid fromCleistanthus indochinensis with a New Carbon Skeleton.Volume 2011, Issue 22, pages 4108 – 4111, August 2011) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2 Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone
By Compound I (440mg, 1.00mmol) be dissolved in 10mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.04g), 1,50% sodium hydroxide solution of 2-Bromofume (3.760g, 20.00mmol) and 6mL.Mixture stirs 24h at 25 degrees Celsius.After 24h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 3 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1, v/v), collects the yellow yellow solid (344mg, 63%) concentrating elution band namely to obtain Compound II per.
1H NMR(500MHz,DMSO-d
6)δ5.04(s,1H),4.82(s,1H),3.94(d,J＝26.5Hz,1H),3.87(d,J＝26.5Hz,2H),3.57(s,2H),2.40(d,J＝14.0Hz,1H),2.39(d,J＝14.0Hz,1H),2.27(s,1H),2.21(s,1H),2.15(s,1H),1.82(s,1H),1.62(s,2H),1.57(d,J＝3.3Hz,1H),1.54(d,J＝3.3Hz,1H),1.50(d,J＝1.2Hz,1H),1.47(d,J＝1.2Hz,1H),1.39(d,J＝15.3Hz,2H),1.34(d,J＝15.3Hz,1H),1.26(dd,J＝32.6,13.7Hz,4H),1.13(d,J＝18.0Hz,2H),1.05(s,6H),0.98(s,1H),0.88(s,12H),0.78(s,3H),0.74(s,1H)。
13C NMR(125MHz,DMSO-d6)δ216.59(s),154.50(s),105.23(s),74.63(s),69.85(s),59.71(s),52.55(s),51.21(s),47.92(s),44.10(s),42.25(s),41.73(s),40.64(s),40.16(s),38.88(s),38.65(s),37.21(s),36.23(s),33.34(d,J＝1.1Hz),32.96(s),29.91(s),27.18(s),26.03(s),24.23(s),23.96(s),20.77(s),18.48(s),17.98(s),16.93(s)。
HRMS(ESI)m/z[M+H]
+calcd for C
32H
52BrO
2:547.3151；found 547.3159.
The synthesis of O-(triazolyl) ethyl derivative derivant (III) of the Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone of embodiment 3 Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone
By Compound II per (273mg, 0.5mmol) be dissolved in the middle of 20mL acetonitrile, add Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) and 1,2,3-triazole (2760mg, 40mmol), mixture reflux 4h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction three times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:0.5, v/v), collects the faint yellow colloidal solid (184.6mg, 67%) that namely faint yellow concentrated elution band obtains compound III.
1H NMR(500MHz,DMSO-d6)δ8.05(d,J＝5.7Hz,2H),4.63(s,1H),4.53(s,1H),4.47(s,1H),4.26(s,1H),4.19(s,1H),3.91(s,2H),2.69(s,1H),2.37(s,1H),2.26(d,J＝13.4Hz,2H),2.20(s,1H),1.89(s,2H),1.81(s,1H),1.64(d,J＝3.5Hz,3H),1.56(s,1H),1.54–1.39(m,3H),1.39–1.35(m,2H),1.30(d,J＝14.4Hz,2H),1.23(d,J＝9.3Hz,2H),1.04(s,6H),0.96(d,J＝1.9Hz,13H),0.86(s,3H),0.78(s,1H).
13C NMR(125MHz,DMSO-d6)δ216.58(s),154.48(s),136.30(s),120.62(s),105.20(s),74.64(s),65.63(s),59.74(s),52.54(s),51.19(s),47.89(s),46.70(s),44.11(s),42.27(s),41.76(s),40.63(s),40.14(s),38.85(s),38.66(s),37.23(s),36.26(s),33.33(s),32.94(s),29.88(s),27.19(s),26.05(s),24.26(s),23.95(s),20.75(s),18.45(s),17.99(s),16.95(s).
HRMS(ESI):m/z[M+H]
+calcd for C
34H
54N
3O
2:536.4216；found:536.4223。
Embodiment 4 compound III anti-erythrocyte low property anemia is tested
Test the therapeutical effect of 1 compound III to post hemorrhagic mice
ICR mice 30, ♀ ♂ half and half, is divided into 3 groups (n=10).Except normal saline group, other group every mice is from orbital vein blood-letting 0.5ml, get blood survey after 24h again and all respectively organize index, then continuously gastric infusion 1 week and blood-letting every day 0.5ml after administration, after last administration 1h, get the full whole bliid platelet analyzer of blood F-800 from orbital venous plexus and carry out red blood cell count(RBC) (10
12/ L).
Table 1 compound III is to because of caused oligocythemic therapeutical effect of losing blood
Compare with model group: * p<0.05
Result shows, blood-letting mice, after taking compound III and treating 7 days, is compared with model group, and its erythrocyte is significantly higher than model group, close to normal saline group.
Two, compound III causes oligocythemic therapeutical effect to cyclophosphamide
To the preventive and therapeutic effect ICR mice 30 of mouse bone marrow cells hemopoietic function damage, ♀ ♂ dual-purpose, is divided into 3 groups (n=10), i.e. normal saline group, modeling group, compound III 1.2mg/kg group, oral administration, every day 1 time.0th, except normal saline group, other respectively organized mice lumbar injection cycli phosphate amine 80mg/kg respectively, then continued administration 3 days on 5th, 10.1h after last administration, gets blood from orbital venous plexus, surveys RBC number (10
12/ L).
Table 2 compound III is on the erythrocytic impact of caused by cyclophosphamide
Compare with model group: * * p<0.01
Result shows, compares with normal saline group, and cycli phosphate amine can make mouse bone marrow cells damage, and causes peripheral blood cells to decline, and compound III group compares with model group, obviously can resist cycli phosphate amine induced mice red blood cell decreased.
Three, compound III is to oligocythemic therapeutical effect caused by benzene
Impact on Induced Aplastic Anemia Mice: Kunming mouse 30, ♀ ♂ dual-purpose, is divided into 3 groups (n=10), except normal saline group, other group mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, the same day of modeling, oral administration simultaneously, every day 1 time, totally 18 days, 1h after last administration, orbital venous plexus gets blood, surveys erythrocyte.
Table 3 compound III is to oligocythemic therapeutical effect caused by benzene
Compare with model group: * * p<0.01
Result shows, administration group compares with model group, obviously can resist the erythrocytic decline of Induced Aplastic Anemia Mice caused by benzene.
Conclusion: compound III significantly can raise erythrocyte, can be used for preparing the medicine for the treatment of anemia.
The preparation of embodiment 5 compound III tablet involved in the present invention
Get the one in the middle of 20 g of compound III or its pharmaceutically acceptable salt, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
The preparation of embodiment 6 compound III capsule involved in the present invention
Get the one in the middle of 20 g of compound III or its pharmaceutically acceptable salt, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Claims (5)
1. one kind has Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof of structure shown in formula III:
2. a kind of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 1, is characterized by: described erythrocyte low property anemia is caused by losing blood.
3. a kind of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 1, is characterized by: described erythrocyte low property anemia is that the erythrocyte caused by chemical substance is low.
4. a kind of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 3, it is characterized by: described chemical substance is benzene, described erythrocyte low property anemia is the aplastic anemia caused by benzene.
5. a kind of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 3, it is characterized by: described chemical substance is cycli phosphate amine, described erythrocyte low property anemia is red blood cell decreased caused by cycli phosphate amine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510103957.3A CN104758295A (en) | 2015-03-10 | 2015-03-10 | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510103957.3A CN104758295A (en) | 2015-03-10 | 2015-03-10 | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104758295A true CN104758295A (en) | 2015-07-08 |
Family
ID=53640627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510103957.3A Pending CN104758295A (en) | 2015-03-10 | 2015-03-10 | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758295A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127421A (en) * | 2014-07-31 | 2014-11-05 | 南京广康协生物医药技术有限公司 | Application of O-(piperidyl)ethyl derivative of Cleistanone in preparation of anti-low erythrocyte anemia drugs |
| CN104147014A (en) * | 2014-06-27 | 2014-11-19 | 南京广康协生物医药技术有限公司 | Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level |
| CN104288159A (en) * | 2014-11-05 | 2015-01-21 | 南京大学 | Application of O-(piperazinyl) ethyl derivative of cleistanone to preparation of medicine for resisting erythrocyte hypoplastic anemia |
-
2015
- 2015-03-10 CN CN201510103957.3A patent/CN104758295A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104147014A (en) * | 2014-06-27 | 2014-11-19 | 南京广康协生物医药技术有限公司 | Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level |
| CN104127421A (en) * | 2014-07-31 | 2014-11-05 | 南京广康协生物医药技术有限公司 | Application of O-(piperidyl)ethyl derivative of Cleistanone in preparation of anti-low erythrocyte anemia drugs |
| CN104288159A (en) * | 2014-11-05 | 2015-01-21 | 南京大学 | Application of O-(piperazinyl) ethyl derivative of cleistanone to preparation of medicine for resisting erythrocyte hypoplastic anemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127421B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| JP5385923B2 (en) | N-heterocyclic carbene platinum derivatives, their preparation, and their therapeutic use | |
| CN104288159B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN104147014B (en) | The application in preparing anti-erythrocyte low property anemia medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN104083385B (en) | The application in the medicine preparing leukocyte increasing of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104800222A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparing drug for preventing red blood cell hypoplastic anemia | |
| CN104922123A (en) | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia | |
| CN105250308A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105078985A (en) | Composition 53083001030571 and application of composition 53083001030571 to drug for resisting low-hematocrit anemia | |
| CN104887667A (en) | Application of Daphmalenine A ramification to preparing medicine for resisting low red blood cell anemia | |
| CN105287570A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105250258A (en) | Composition and application of composition in medicine for resistance of erythrocyte low anemia | |
| CN104758295A (en) | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug | |
| CN105287525A (en) | Composition and application of composition in medicine for resisting low red blood cell type anemia | |
| CN105193815A (en) | Composition and application thereof in drugs for preventing low-erythrocyte anemia | |
| CN105250293A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN106038551A (en) | Application of composition of Schiglautone A derivatives in preparation of low-erythrocyte anemia preventive drugs | |
| CN105343083A (en) | Composition and application of composition in medicines for resisting low erythrocyte anemia | |
| CN105497038A (en) | Composition and application thereof to low-erythrocyte anemia resistant medicament | |
| CN105343085A (en) | Composition and application thereof in low erythrocyte anemia resistant drugs | |
| CN105287455A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105395555A (en) | Composition and application thereof to medicine resistant to red cell hypoplastic anemia | |
| CN107929288A (en) | The miscellaneous source terpene piperazinyl of guava dialdehyde and tetrazole radical derivative composition are used to prepare anti-anemia action medicine | |
| CN105616403A (en) | Composition and application thereof to low red blood cell anemia resisting medicine | |
| CN106074528A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-erythrocyte low property anaemia medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150708 |
|
| RJ01 | Rejection of invention patent application after publication |